ERS/ESTS statement on the management of pleural infection in adults

Ehab O. Bedawi, Sara Ricciardi, Maged Hassan, Michael R. Gooseman, Rachelle Asciak, Olalla Castro-Añón, Karin Armbruster, Martina Bonifazi, Sarah Poole, Elinor K. Harris, Stefano Elia, Rafael Krenke, Alessandro Mariani, Nick A. Maskell, Eva Polverino, Jose M. Porcel, Lonny Yarmus, Elizabeth P. Belcher, Isabelle Opitz and Najib M. Rahman

1Oxford Pleural Unit, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. 2Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK. 3NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. 4Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK. 5Unit of Thoracic Surgery, San Camillo Forlanini Hospital, Rome, Italy. 6PhD Program Alma Mater Studiorum, University of Bologna, Bologna, Italy. 7Chest Diseases Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. 8Department of Thoracic Surgery, Hull University Teaching Hospitals NHS Trust, Hull York Medical School, University of Hull, Hull, UK. 9Department of Respiratory Medicine, Queen Alexander Hospital, Portsmouth, UK. 10Department of Respiratory Medicine, Mater Dei Hospital, Msida, Malta. 11Department of Respiratory Medicine, Lucus Augusti University Hospital, EOXI Lugo, Cervo y Monforte de Lemos, Lugo, Spain. 12C039 Biodiscovery Research Group HULA-USC, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. 13Department of Medicine, Section of Pulmonary Medicine, Herlev-Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. 14Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy. 15Respiratory Diseases Unit, Azienda Ospedaledio-Universitaria “Ospedali Riuniti”, Ancona, Italy. 16Department of Pharmacy and Medicines Management, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. 17Bodleian Health Care Libraries, University of Oxford, Oxford, UK. 18Department of Medicine and Health Sciences “V. Tiberio”, University of Molise, Campobasso, Italy. 19Thoracic Surgical Oncology Programme, Policlinico Tor Vergata, Rome, Italy. 20Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Warsaw, Poland. 21Thoracic Surgery Department, Heart Institute (InCor) do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil. 22Academic Respiratory Unit, University of Bristol, Bristol, UK. 23Pneumology Department, Hospital Universitari Vall d’Hebron, Institut de Recerca Vall d’Hebron, Barcelona, Spain. 24Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, IRBLeida, Lleida, Spain. 25Division of Pulmonary and Critical Care, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 26Department of Thoracic Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. 27Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland. 28Chinese Academy of Medical Health Sciences, University of Oxford, Oxford, UK.

Corresponding author: Ehab O. Bedawi (eombedawi1@sheffield.ac.uk)

Shareable abstract (@ERSpublications)
Intrapleural fibrinolytic-based therapy has revolutionised pleural infection management, but surgical intervention remains vital in select patients. Studies into early and targeted escalation of treatment based on risk stratification are now required. https://bit.ly/3y6rZ8a


This single-page version can be shared freely online.

Abstract
Pleural infection is a common condition encountered by respiratory physicians and thoracic surgeons alike. The European Respiratory Society (ERS) and European Society of Thoracic Surgeons (ESTS) established a multidisciplinary collaboration of clinicians with expertise in managing pleural infection with the aim of producing a comprehensive review of the scientific literature. Six areas of interest were identified: 1) epidemiology of pleural infection, 2) optimal antibiotic strategy, 3) diagnostic parameters for chest tube drainage, 4) status of intrapleural therapies, 5) role of surgery and 6) current place of outcome prediction in management. The literature revealed that recently updated epidemiological data continue to show an overall upwards trend in incidence, but there is an urgent need for a more comprehensive characterisation of the burden of pleural infection in specific populations such as immunocompromised hosts. There is a sparsity of regular analyses and documentation of microbiological patterns at a local level to inform geographical
variation, and ongoing research efforts are needed to improve antibiotic stewardship. The evidence remains in favour of a small-bore chest tube optimally placed under image guidance as an appropriate initial intervention for most cases of pleural infection. With a growing body of data suggesting delays to treatment are key contributors to poor outcomes, this suggests that earlier consideration of combination intrapleural enzyme therapy (IET) with concurrent surgical consultation should remain a priority. Since publication of the MIST-2 study, there has been considerable data supporting safety and efficacy of IET, but further studies are needed to optimise dosing using individualised biomarkers of treatment failure. Pending further prospective evaluation, the MIST-2 regimen remains the most evidence based. Several studies have externally validated the RAPID score, but it requires incorporating into prospective intervention studies prior to adopting into clinical practice.